
DURECT Corporation DRRX
Quartalsbericht 2025-Q2
hinzugefügt 16.05.2026
DURECT Corporation DSO 2011-2026 | DRRX
DSO Jährlich DURECT Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 96.2 | 285 | 93.7 | 91 | 17 | 28.6 | 34.5 | 17.6 | 30 | 42.4 | 39.9 | 55.9 | 14.9 | 37.6 | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 285 | 14.9 | 63.2 |
DSO Vierteljährlich DURECT Corporation
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 85.8 | 191 | 48 | 144 | 175 | 57.2 | 59.3 | 107 | - | 12.3 | 21.1 | 177 | - | 37.1 | 35.8 | 39.9 | - | 47.4 | 3.5 | 41 | 12 | 19.6 | 8.44 | 45 | 44.2 | 19.9 | 47 | 54.1 | 11.1 | 10.4 | 50.2 | 35.3 | 29.9 | 28.1 | 33.4 | 42.7 | 39.2 | 42.8 | 45.7 | 41.5 | 45.4 | 45.5 | 42.3 | 32.4 | 50 | 72.3 | 54.7 | 49.6 | 60.6 | 51.6 | 41.2 | 6.22 | 35.2 | 38.8 | 40.2 | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 191 | 3.5 | 50.2 |
DSO anderer Aktien in der Arzneimittelhersteller
| Name | DSO | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Cumberland Pharmaceuticals
CPIX
|
382 | $ 5.87 | 6.53 % | $ 87.2 M | ||
|
Endo International plc
ENDP
|
79.9 | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
55.1 | - | - | $ 36.6 M | ||
|
HEXO Corp.
HEXO
|
71.3 | - | 2.45 % | $ 38.1 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
86.6 | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
71.7 | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
117 | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
63.1 | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
122 | - | - | $ 142 M | ||
|
Cronos Group
CRON
|
61.7 | $ 2.74 | 0.37 % | $ 1.05 B | ||
|
Harrow Health
HROW
|
87.8 | $ 33.0 | 0.12 % | $ 1.21 B | ||
|
Athenex
ATNX
|
89.9 | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
49.9 | - | - | $ 2.06 B | ||
|
Catalent
CTLT
|
80.1 | - | - | $ 11.5 B | ||
|
Organogenesis Holdings
ORGO
|
106 | $ 2.66 | - | $ 337 M | ||
|
Pacira BioSciences
PCRX
|
50.3 | $ 23.35 | -0.55 % | $ 1.08 B | ||
|
Eagle Pharmaceuticals
EGRX
|
65.5 | - | -39.89 % | $ 27.7 M | ||
|
Bausch Health Companies
BHC
|
79.8 | $ 5.47 | 0.37 % | $ 2 B | ||
|
Canopy Growth Corporation
CGC
|
62.7 | $ 1.04 | -2.8 % | $ 112 M | ||
|
Tilray
TLRY
|
52.8 | $ 5.29 | -3.11 % | $ 3.27 B | ||
|
Aurora Cannabis
ACB
|
99.8 | $ 3.46 | -2.81 % | $ 190 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
65.5 | $ 1.1 | 3.77 % | $ 1.37 M | ||
|
Jupiter Wellness
JUPW
|
51.9 | - | - | $ 33.6 M | ||
|
Lannett Company
LCI
|
83.1 | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
93 | $ 1.12 | -0.88 % | $ 107 M | ||
|
Evolus
EOLS
|
62.9 | $ 6.09 | -5.58 % | $ 393 M | ||
|
Emergent BioSolutions
EBS
|
58.6 | $ 8.45 | 0.96 % | $ 433 M | ||
|
Veru
VERU
|
91.5 | $ 2.35 | 5.86 % | $ 34.4 M | ||
|
Neoleukin Therapeutics
NLTX
|
3.46 | - | - | $ 193 M | ||
|
cbdMD
YCBD
|
13.4 | $ 0.76 | -2.32 % | $ 3.06 M | ||
|
Assertio Holdings
ASRT
|
268 | $ 23.44 | 0.3 % | $ 150 M | ||
|
ProPhase Labs
PRPH
|
111 | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
34.7 | - | - | $ 1.42 B | ||
|
PetIQ
PETQ
|
43.1 | - | 1.64 % | $ 400 M | ||
|
Recro Pharma
REPH
|
62.7 | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
138 | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
2.74 | $ 0.73 | 3.0 % | $ 36.5 M | ||
|
PLx Pharma
PLXP
|
14.1 | - | -27.8 % | $ 2.56 M | ||
|
Viatris
VTRS
|
67 | $ 16.65 | 1.15 % | $ 19.4 B | ||
|
Zomedica Corp.
ZOM
|
31 | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
14.6 K | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
43.3 | $ 0.79 | -2.06 % | $ 28.4 M | ||
|
China Pharma Holdings
CPHI
|
20.9 | $ 0.76 | -0.29 % | $ 3.26 M | ||
|
TherapeuticsMD
TXMD
|
2.3 K | $ 2.12 | 0.47 % | $ 24.5 M |